It’s about time
COVID-19 vaccines have shown the public just how fast we can develop, assess and approve medicines. How can we accelerate these timelines outside of a pandemic?
FACILITATED BY
IAN MUIR | Chief Executive Officer | Porton Biopharma
PANELLISTS INCLUDE
PAUL STOTT | Chief Executive Officer | Seda Pharmaceutical Development Services
JILL RECKLESS | Chief Executive Officer | RxCelerate
FLIC GABBAY | Managing Partner | tranScrip
SANDY DOUGLAS | Research Group Leader | The University of Oxford
NICK SMITH | Associate Director of Operations | Cobra Biologics